Poor response to chemotherapy in patients with breast cancer is often associated with overexpression of HER -2 / neu. Interference with HER -2 mRNA translation by means of antisense oligonucleotides might improve the efficacy of chemotherapy. To test this hypothesis, eight breast cancer cell lines and a normal human fibroblast cell line were examined for their level of HER -2 expression, their sensitivity to phosphorothioate antisense oligonucleotides ( AS HER -2 ODN ), and to various chemotherapeutic agents, and the combination of the two. No correlation was found between the intrinsic HER -2 level and either the sensitivity to a particular chemotherapeutic agent alone, or the amount of growth inhibition observed with a specific AS HER -2 ODN concentration. Although sequence specificity and extent of AS HER -2 ODN inhibition of HER -2 synthesis were somewhat higher in the HER -2 overexpressing MDA -MB -453 and SK -BR -3 cells, we found that antisense treatment significantly sensitized all of the breast cancer cells, even MDA -MB -231 and MDA -MB -435 cells, with approximately basal levels of HER -2, to various chemotherapeutic agents. In addition, the combination of AS HER -2 ODN and taxol was shown to synergistically induce apoptosis in MDA -MB -435. These results demonstrate that overexpression of HER -2 would not be a prerequisite for the effective use of AS HER -2 ODN as a combination treatment modality for breast cancer and suggest that the use of AS HER -2 ODN, as part of a combination treatment modality, need not be limited to breast tumors that display elevated levels of HER -2. Cancer Gene Therapy ( 2001 ) 8, 728 -739 
T he HER -2 /neu (or c-erbB -2 ) proto -oncogene encodes a 185 -kDa transmembrane glycoprotein (HER -2) with an intracellular tyrosine kinase domain. HER -2 shares extensive sequence homology with the epidermal growth factor receptor (EGFR ) family that also includes EGFR ( or ErbB -1) and neuregulin -specific ErbB -3 and ErbB -4. In contrast to other family members, HER -2 has no identified high -affinity ligand. HER -2 participates in lateral signal transduction through formation of heterodimers with ligand-activated ErbB -1, -3 or -4 as preferred dimermates. After dimerization, cross -phosphorylation within the kinase domains generates differentiated docking sites for cytoplasmic signaling molecules that eventually activate the MAP -kinase pathway. 1 -4 Oncogenic activation of HER -2 is associated with gene amplification or transcriptional dysregulation that leads to constitutive overexpression of HER -2 and enhanced mitogenic signaling. 5 -11 It has also been associated with more aggressive tumor growth and poorer patient prognosis. 7, 8 In particular, overexpression of HER -2 is found in nearly 30% of primary breast cancers 7, 8 and in a similar fraction of other human adenocarcinomas including ovary and lung (reviewed in Ref. 12 ). In 10-20% of HER -2-overexpressing breast tumors, HER -2 mRNA and protein overexpression occurs in the absence of increased gene copy number. Furthermore, increased expression of the transfected HER -2 in breast cancer cells has been associated with induced chemoresistance to paclitaxel ( Taxol, TAX ). 13 Though controversial (for critical review see Ref. 14 ) , clinical data also indicate a poor response to adjuvant and hormonal therapy of patients whose breast cancers overexpress HER -2.
Response to low -dose chemotherapy might be improved by targeted interference with HER -2 expression. Thus, the combination of the murine anti -HER -2 antibody 4D5 and cis -diamminedichloroplatinum (CDDP) has resulted in a two-log increase in CDDP-induced cytotoxicity in HER -2 -overexpressing cell lines, as well as in histopathologically judged complete remissions in athymic mice bearing HER -2 -overexpressing human breast cancer xenografts. 15 Using a humanized form of 4D5, rhuMAb HER2, the increased efficacy of this combination treatment has also been recently demonstrated for cyclophosphamide, doxorubicin ( DOX ), methotrexate, TAX, etoposide, and vinblastine (VBL ). 16 Interference with HER -2 mRNA translation may be a more advantageous approach in combination therapy than down -modulation of the already expressed and cellsurface located HER -2 protein. This is accomplished by means of sequence-specific antisense oligonucleotides ( AS ODNs ) that hybridize with the mRNA and initiate its RNase H -mediated hydrolysis. 17 Previously, we have shown that the phosphorothioate pentadecamer 5 0 TCCATGGTGCTCACT3 0 , complementary to the HER -2 mRNA initiation codon region (AS HER -2 ODN ), inhibited HER -2 protein expression and sensitized HER -2 -overexpressing ovarian carcinoma SK -OV-3 cells to radiotherapy. 18 More recently, the same AS ODN was found to increase the response to TAX in selected breast cancer cell lines. 19 Here, we describe the results of such chemosensitization with five chemotherapeutic agents, acting through different mechanisms, in eight breast cancer cell lines differing in their HER -2 level. We attempted to determine the relationship between HER -2 expression levels and the cell line's response to antisense treatment. Our findings suggest that overexpression of HER -2 is not required for chemosensitization by AS HER -2 ODN treatment, and that AS HER -2 ODN -based therapy may be an effective treatment for breast cancers that do not overexpress HER -2, thus broadening the clinical potential of AS HER -2 ODN therapy.
METHODS

Cell lines and cell culture
Most of the cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA ). Human breast carcinoma cell lines MDA -MB -435 and MCF7 /Adr ( adriamycin-resistant clone of MCF7 ) were provided by the GUMC Core Facility. H500 is a normal human fibroblast cell line established from an infant foreskin. Cell culture media and medium ingredients were from Biofluids (Rockville, MD ).
MDA -MB-231 and MDA -MB -435, MCF7, MCF7/ Adr, and SK -BR -3 cells were cultured in improved MEM ( IMEM ) supplemented with 10% heat -inactivated fetal bovine serum (FBS ), 2 mM L -glutamine, and 50 g/mL each of penicillin, streptomycin, and neomycin. MCF -10A cells were grown in DMEM, supplemented as above. H500 cells were grown in EMEM containing 1 mM sodium pyruvate and 1 mM nonessential amino acids in addition to FBS, glutamine, and antibiotics. MDA -MB -453 cells were cultured in RPMI medium 1640 with 10% FBS, glutamine, and gentamicin. Hs 578T cells were grown in the mixture of IMEM and 10% NCTC medium 109, supplemented with 50 ng/ mL insulin, 30 ng /mL EGF, and (as specified above ) FBS, glutamine, pyruvate, nonessential amino acids, and antibiotics.
Drug -sensitivity assay
The list of drugs tested includes vinblastine sulfate ( VBL; Fujisawa USA, Deerfield, IL ), Taxol (TAX; Bristol -Myers Squibb, Princeton, NJ ), Adrucil (5 -FU; Pharmacia and Upjohn, Kalamazoo, MI ), Platinol -AQ ( CDDP, Bristol -Myers Squibb ) and doxorubicin ( DOX; Bedford Labs, CA ).
In two or more independent experiments, 5Â10 3 cells in 100 L of an appropriate medium were plated in duplicate in a 96-well microplate. Following overnight incubation, 100 L of medium with, or without for control, the specific drug was added to each well. After incubation for 72 hours at 378C in a humidified atmosphere containing 5% CO 2 , the wells were washed with phosphate -buffered saline (PBS ) and the cell viability XTT-based assay performed according to the manufacturer's protocol (Boehringer Mannheim, Indianapolis, IN ). In the presence of an electron -coupling reagent, XTT, sodium 3 0 -[ 1-(phenylamino-carbonyl)-3,4 -tetrazolium ]-bis( 4 -methoxy -6 -nitro )benzene sulfonate, is converted into orange formazan by dehydrogenase in the mitochondria of living cells. The formazan absorbance, which correlates to the number of living cells, was measured at 450 nm using a microplate reader ( Molecular Devices, Menlo Park, CA ). The IC 50 was interpolated from the graph of the log of drug concentration versus the fraction of surviving cells.
Oligonucleotide and oligonucleotide -drug combination treatments
The phosphorothioate sequence specific antisense HER -2, complementary to the initiation codon region ( 5 0 -TCC ATG GTG CTC ACT-3 0 ), and the control, non-sequence specific scrambled ( 5 0 -CTA GCC ATG CTT GTC -3 0 ) ODNs were synthesized and purified by reverse phase HPLC by The Midland Certified Reagent (Midland, TX ). Screening of both the antisense and scrambled sequences against the GenBank Database indicated that the antisense ODN had homology only to HER -2, whereas there was no homology between the scrambled ODN and any sequence in the database.
ODN -lipofectin complexes were prepared as recommended by the manufacturer using Lipofectin 1 reagent ( 1 mg /mL; Life Technologies, Gaithersburg, MD ). Briefly, 7 l of lipofectin was diluted into 100 l of serumand antibiotics -free medium, depleted medium (DM ) and allowed to stand at room temperature for 10 minutes. The diluted lipofectin was gently mixed with 100 L of a 30 M ODN solution, incubated for an additional 20 min, and combined with 800 l of DM to yield 3 M ODN. The 3 M ODN solution was diluted with DM media to the desired concentration. In our study, cells were treated with oligonucleotides at 0.03 -3 M concentration.
For ODN treatment, cells, seeded and grown as above, were washed twice with DM and then overlayed with 50 l of the ODN -lipofectin complex. After 12 hours ( or 6 hours in the case of the MDA -MB -453 cells), 50 l of DM supplemented with 20% FCS, 4 mM glutamine, and antibiotics was added, and incubation was continued for an additional 12 hours. Following addition of 100 l of a specific supplemented medium with or without drug, incubation was continued for up to 72 hours.
For the apoptosis assay, cells were seeded in a six -well plate ( 5Â10 4 per well) and treated with 0.3 M of ODN followed by 1 nM taxol incubation as above (24 hours each treatment).
Apoptosis flow cytometric assay
The assay was performed using the Annexin V-FITC apoptosis detection kit (Trevigen, Gaithersburg, MD ) according to the manufacturer's protocol. In brief, control and treated cells were washed with PBS, harvested with trypsin, collected after centrifugation at 1000Âg for 7 min at 48C, and washed once with cold PBS. The pelleted cells were resuspended in the incubation mixture containing propidium iodide and the calcium -dependent phospholipidbinding protein conjugated to FITC. After 15 min, the binding buffer was added, and flow cytometry was performed within 1 hour using a FACScan flow cytometer ( Becton Dickinson, Mountain View, CA ).
Preparation of cell lysates
In preparation for Western analysis, cells, harvested and washed as above, were resuspended in 50-100 l of cold lysis buffer, composed of PBS, 1% nonidet P -40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS ), 0.1 mg /ml phenylmethylsulfonyl fluoride ( PMSF ), 30 g/ ml aprotinin, and 1 mM sodium orthovanadate. After 20 min in an ice bath, lysates were passed through a 21 -gauge needle, incubated on ice an additional 30 min, and then centrifuged at 15,000Âg for 20 min at 48C. Protein concentration of the supernatants was measured using the Pierce Micro BCA protein assay reagent (Pierce, Rockford, IL ) and the proteins stored at À 808C.
Western blot analysis
Primary anti -human HER -2 and Bcl -2 rabbit polyclonal antibodies, Neu ( C-18 ) and N -19, respectively, as well as secondary peroxidase -conjugated anti -mouse antibodies were obtained from Santa Cruz Biotechnology ( Santa Cruz, CA ). Anti-human glyceraldehyde -3 -phosphate dehydrogenase (GAPDH ) rabbit polyclonal and C2 -10 poly( ADPribose) polymerase mouse monoclonal antibodies were purchased from Trevigen. Peroxidase -conjugated goat anti -rabbit antibody was obtained from Jackson ImmunoResearch Laboratories (West Grove, PA ).
Lysates containing 40 g of total protein were denatured, separated by discontinuous 12% polyacrylamide/SDS gel electrophoresis, and electroblotted onto Protran BA 85 nitrocellulose transfer membrane ( Schleicher & Schuell, Keene, NH ). To block nonspecific binding, the membrane was incubated at room temperature for 1 hour with 5% nonfat dry milk in 10 mM Tris -HCI buffer, pH 8.0, containing 150 mM NaCl and 0.05% Tween 20 ( TBST ). The blot was probed for 1 hour with primary antibody and washed three times (15 minutes each ) with TBST. The specific protein was detected using secondary horseradish peroxidase -conjugated IgG, ECL Western blotting detection reagent, and Hyperfilm ECL ( Amersham, Piscataway, NJ ). Densitometry was performed by scanning the films on a PDI (Huntington Station, NY ) scanner, model DNA 35, supported by PDI analysis software, Quantity One, version 2.0.
RESULTS
Estimation of relative HER -2 levels
The HER -2 levels in some of the breast cancer cell lines used here have previously been estimated or quantified via immunoblot analysis with various antibodies by a number of investigators. 9, 20, 21 As there are some inconsistencies in these reports regarding HER -2 expression levels, we independently established HER -2 levels for the cell lines used in this study. An affinity-purified rabbit polyclonal antibody raised against a peptide corresponding to amino acids 1169 -1186, mapping at the carboxy terminus of HER -2, was employed. A representative Western blot analysis is shown in Figure 1 . Equal amounts of protein was loaded in each lane, which was confirmed by Western analysis using an anti -GAPDH antibody. Densitometric estimations of the HER -2 level of these cell lines, relative to normal fibroblast cell line H500, are included in the last column of Table 1 well of a 96 -well plate resulted in a confluence of approximately 50% within 18-24 hours. This is the cell density that was optimal for lipofection, i.e., cell treatment by ODN complexed with Lipofectin 1 . 22 Untreated cells, which serve as controls, needed more than 72 hours of additional incubation to reach full confluence. Therefore, duration of drug exposure was limited to 72 hours in all experiments. Thus, in the drug -alone regimen, adherent cells were treated with a drug, and viable cells were detected 72 hours later by the XTT cytotoxicity assay. 23 In the ODNalone regimen, lipofection, i.e., transfection by ODN complexed with Lipofectin 1 , 22 was performed in serumdepleted medium for 12 hours followed by medium restoration. In the ODN plus drug combination treatment, the drug was added 12 hours after medium restoration and the XTT assay was performed after an additional 72 hours incubation. These times and conditions were found to be acceptable for all of the cell lines used in this study.
The IC 50 values, determined 72 hours after drug addition ( Table 1 ) , span a broad range of concentrations from picomolar to millimolar. This variation is drug dependent. Comparison of the IC 50 values for a particular drug shows that MCF7, SK -BR -3, and MDA -MB -231 form a group with high resistance to VBL. Similarly, MCF7, MCF7 /Adr ( a DOX -resistant clone of MCF7), and ZR -75-1 cells display elevated resistance to TAX. As expected, MCF7 /Adr cells are found to be the least sensitive to DOX, with an IC 50 of 5100 nM. In the case of CDDP, four cell lines (MCF7, ZR -75 -1, MDA -MB-231, and MDA -MB -435) have IC 50 values higher than the IC 50 for the control MCF -10A and H500 cell lines. In contrast, the IC 50 values for 5-FU in these eight cell lines are all lower than those found for control H500 ( Table 1) . Comparison of the IC 50 values with HER -2 levels indicates that there is no correlation between intrinsic HER -2 levels and drug sensitivity in these breast cancer cell lines.
Inhibition of HER -2 synthesis and cell growth by AS HER -2 ODN
The potential of antisense ODNs to down -modulate HER -2 and to inhibit breast cancer cell proliferation in culture has been demonstrated in several in vitro studies. However, there are reports suggesting that breast cancer cells with HER -2 amplification are subject to specific growth inhibition by ODNs whereas the proliferation of cells without overexpression of HER -2 is not. 24 -26 As the majority of breast cancers do not overexpress HER -2, for AS HER -2 ODNbased therapy to be a viable option for breast cancer treatment it would be important to determine if breast cancer cells that do not overexpress HER -2 can also respond. Thus, while examining the effect of AS HER -2 ODN on multiple breast cancer cell lines, we will focus on comparison between MDA -MB -453, which overexpresses HER -2, and MDA -MA -231 and MDA -MB -435, both of which have approximate basal levels of the protein.
In the current study, we examined the effects of a phosphorothioate pentadecamer 5 0 TCCATGGTGCTCACT3 0 complementary to the initiation codon region of HER -2 mRNA on synthesis of HER -2 protein and cell proliferation. RAIT, PIROLLO, RAIT, ET AL: AS HER-2 ODN AND CHEMOTHERAPY Previous studies using a series of AS HER -2 ODNs complementary to the area around and including the initiation codon indicated that this particular oligomer resulted in the most efficient inhibition of HER -2 protein synthesis ( data not shown). AS ODNs targeted to other regions of the gene had been previously found to be less effective in inhibiting protein synthesis (E. Chang, unpublished data ). HER -2 protein synthesis and cell proliferation were examined at 48 and 96 hours, respectively, after the start of lipofection. Previous time course studies had shown that 48 hours was the time that the specific AS ODN effect on the HER -2 protein level was maximal (data not shown ). The use of 96 hours for cell proliferation studies was based on the total time of ODN ( 24 hours ) and drug exposure ( 72 hours ) in the combination treatment as described above. To establish the sequence specificity, a scrambled HER -2 ODN ( SC ) (5 0 CTAGCCATGCTTGTC3 0 ), which has the same nucleotide composition as the AS HER -2 ODN, was used as a control. A search against GenBank sequences determined that the AS ODN had homology only to HER -2, whereas there was no homology between the control scrambled ODN and any sequence in the database.
The effect of the AS HER -2 ODN on the level of HER -2 protein in three breast cancer cell lines is shown in Figure 2 . These three cell lines are representative of breast cell lines that either overexpress HER -2 ( MDA -MB-453 ) or have Even at the highest concentrations tested, the control SC HER -2 ODN had virtually no effect on HER -2 synthesis in any of the cell lines, showing that in these cells the inhibition of HER -2 synthesis by the AS ODN is sequence specific ( Fig 2 ) . In no instance did the lipofectin alone have any effect on HER -2 protein synthesis (data not shown).
The data in Figure 3 1 M) . Surprisingly, the data from Figures 2 and 3 and Table 1 indicate that there is no clear correlation between the intrinsic level of HER -2, the extent of HER -2 protein inhibition by AS ODN, and the level of cell killing. Although the magnitude of the effect does not correlate with HER -2 level there is, with the exception of MCF7, a significant AS ODN specific effect on both the HER -2 protein level and cell survival in the breast tumor cell lines.
Comparing the effects of SC ODN on HER -2 level ( Fig 2 ) and cell survival (Fig 3 ) , one can conclude that the latter is somewhat more sensitive to treatment by the SC ODN. This is likely to be a consequence of the ability of the phosphorothioate ODN to interact with heparinbinding cell -surface receptors and other proteins in a non -sequence specific manner. 27 Despite this, there is still a significant difference in the percent of cell survival between treatment with AS ODN and SC ODNs in all of the tumor cell lines, with the exception of MCF7, indicating that the observed response is due primarily to a sequence-specific, antisense effect.
Chemosensitization by AS HER -2 ODN
Once the sensitivity of the cell lines to chemotherapeutic agents and ODNs themselves was established, drug and ODN combination treatment of cells was performed. As the AS HER -2 alone was found to be effective in inhibiting cell growth, ODN concentrations that were below the IC 50 values for the AS ODNs were used in these studies to assess chemosensitization by AS HER -2 treatment. Thus, different ODN concentrations were required for each cell line. The ratio of IC 50 values measured in the presence of the control SC and AS ODNs, IC 50 SC /IC 50 AS , was used to characterize the degree of sensitization. Figure 4 shows representative cell survival curves for the combination of DOX and ODNs in three breast cancer and one control cell lines Tables 2-6 . As shown in these tables, the level of sensitization differs greatly between cell lines for each drug. Similarly, the degree of AS ODN sensitization of a particular cell line was found to vary from drug to drug. For example, at a concentration of 0.3 M, the degree of sensitization of the low HER -2 -expressing cell line MDA -MB -435 varies from 7.8 -fold for CDDP to 9.3-fold for TAX, 9.9-fold for 5 -FU, 10.2 -fold for VBL, and 28.8 -fold for DOX. The other low HER -2-expressing cell line, MDA -MB -231, also displays dramatic and variable chemosensitization by an even lower AS HER -2 concentration (0.1 M ). The fold sensitization for this cell line ranges from 3.9 -fold for TAX to 25 -fold for CDDP, 53.7 -fold for DOX and even 161 -fold for VBL. At the same AS HER -2 ODN concentration of 0.1 M, a lower but still significant increase in drug sensitivity is observed in the MDA -MB -453 cell line that overexpresses HER -2, i.e., 6.6 -fold increase with CDDP, 8.5 -fold for DOX, and 9.7 -fold for VBL. As discussed above and shown in Figure 3 , these cells are the most responsive to AS HER -2 ODN treatment, having the highest level of cell killing and, thus, a low IC 50 (0.17 M). Therefore, as mentioned above, due to the extent of cell killing by AS HER -2 ODN alone with this cell line, we were unable to use AS ODN concentrations higher than 0.1 M in these studies.
The variability of the extent of AS ODN sensitization between drugs is also demonstrated in SK -BR -3 cells. Treated with an antisense concentration of 0.3 M, their degree of sensitization also varied widely, from 7.9 -fold with CDDP to greater than 63-fold with 5-FU.
As a rule, the fold sensitization increased with increasing AS ODN concentration. The only exception observed was for MDA -MB -231 cells treated with the combination of AS ODN and TAX (Table 4 ) . However, these cells were also highly sensitive to the combination of SC ODN and TAX. Thus, the corresponding decrease in IC 50 for the control SC ODN contributed to the decrease in sensitization with this combination. It should also be noted that of the five chemotherapeutic agents used, 5-FU is the least selective, being the only agent to which noncancerous human fibroblast cell line H500 was sensitized by treatment with AS ODN ( Table 6 ). It is interesting to compare the response of MDA -MB -435 and MDA -MB -231 cells, both of which have approximately basal levels of HER -2 expression, to the ODN and drug combination treatment. MDA -MB -435 was established from the carcinoma of a patient who had not received chemotherapy, whereas the patient who was the source for MDA -MB -231 had received chemotherapy with 5 -FU, prednisone, cytoxan, DOX, and methotrexate. 28 Not unexpectedly, MDA -MB -231 cells display higher resistance to the drugs tested here than MDA -MB -435 cells ( Table 1) . However, MDA -MB -231 cells were more sensitive to AS ODN cell killing alone than MDA -MB -435 cells (Fig 3 ) . Moreover, as described above, and as shown in Tables  2 -6 , it is evident that the extent of chemosensitization by AS HER -2 ODN is consistently higher for MDA -MB -231. Therefore, the final level of sensitization observed after combination treatment is not solely dependent on the HER -2 expression in the cells, but is the result of a number of contributing factors. These include the AS ODN concentration, and the mechanism of action of the drug used, as well as the history and complex genetic heterogeneity of the tumor cells themselves that plays a role in determining their intrinsic IC 50 values.
Induction of apoptosis following combination treatment
The XTT-based cell survival assay used in the above experiments is not a direct measure of cancer cell death by the combination treatment. Therefore, FACS analysis was used to examine the level of apoptosis in MDA -MB -435 cells with the combination of 0.3 M AS ODN ( for 24 hours ) followed by 24 -hour treatment with 1 M TAX. The results of the apoptosis assay are shown in Figure 5 . In each panel of Figure 5 , the lower left quadrant represents viable cells with an intact, undamaged membrane. Cells in the lower right quadrant are in early apoptosis and are detected via fluorescence of Annexin V-FITC that binds to the flipped phosphatidylserine of affected cell membranes. 29 Cells in the upper right quadrant are in late apoptosis or necrosis with both flipped and disrupted membranes that also bind fluorescent propidium iodide. The dot plots in Figure 5A and B indicate that in samples treated with TAX or AS ODN alone, only 6.0% and 7.7%, respectively, of the cells are in apoptosis (sum of upper and lower right quadrants ), whereas the combination of drug and AS ODN results in a significant increase in the fraction of apoptotic cells to 28.1% ( Fig 5D ) . That this effect is AS HER -2 ODN -specific is shown in Figure 5C , where the percentage of apoptotic cells after treatment with the combination of the SC ODN and TAX is identical to that resulting from TAX treatment alone.
Additional evidence of the enhancement of programmed cell death by the combination of AS HER -2 ODN treatment and TAX is presented in Figure 6 . Poly( ADPribose) polymerase proteolytic cleavage was examined in MDA -MB -435 cells treated with the combination of AS HER -2 ODN (0.3 M, for 24 hours ) followed by 1 nM TAX for 24 hours or either treatment alone. An early marker of apoptosis in mammalian cells, 30 this cleavage results in liberation of an 85 -kDa fragment from the 113-kDa full -length enzyme. As evidenced in Figure 6A , significant proteolytic cleavage is present only in those cells receiving the combination treatment. We also examined the effects of the combination treatment on another marker of apoptosis, Bcl -2 ( Fig 6B ) . Bcl -2 is a known antiapoptotic protein, 31 the level of which has been shown to decrease after treatment with TAX. 32 Whereas this TAX -induced decrease in Bcl -2 expression is evident in the MDA -MB -435 cells treated with TAX alone, there was an additional 4-fold decrease in protein level in the cells receiving the combination treatment. GAPDH was used as a control for protein loading (Fig 6C ) .
Therefore, at least with TAX, the observed increase in chemosensitivity and cell death is due in large measure to a synergistic effect of the combination of AS HER -2 ODN and TAX on apoptosis.
DISCUSSION
Antisense ODN -mediated down -regulation of HER -2 expression has been the subject of several studies, performed on one, 33, 34 24, 37 human breast cancer cell lines. With one exception, 25 the HER -2 -overexpressing cell line SK -BR -3 has been used in all studies and is compared most often to MCF7 cells, which do not have an amplified HER -2 gene and possess only a basal level of its protein product. 9 Initially, it was observed that, at an AS ODN concentration of 2 M, the HER -2 level was reduced differentially within 24 hours in SK -BR -3 and MCF7 cells by 75% and 50%, respectively. 35 Colomer et al 24 combined HER -2 protein analysis and a cell proliferation assay. This study showed that, for SK -BR -3 cells, the growth, HER -2 level, and DNA synthesis are reduced in a dose -dependent manner. The response of MCF7 cells to AS ODN was not quantitated but was described as being minimal and non-sequence specific. 24 Liu and Pogo 25 employed two HER -2-overexpressing ductal carcinoma cell lines, BT474 and T47D, as well as noncancerous human breast cell line MCF10F to examine the effect of AS HER -2 ODN on breast cancer cell lines. These authors concluded that anti -HER -2 ODNs would only be effective in the breast cancer cells that express elevated HER -2, not in HER -2 negative or lowexpressing cells. Conflicting results were reported by Roh et al, 37 who compared the antisense response of BT474 ( that has overexpression and gene amplification similar to SK -BR -3 ) and MCF7 cell lines. They found equal sensitivity of these cells to HER -2 inhibition. However, there was a more than 3 -fold higher level of BT474 cell growth inhibition.
Despite minor differences in details, all of the above studies support the feasibility of inhibiting breast cancer cell proliferation via antisense suppression of HER -2 expression. The majority also support the hypothesis that anti -HER -2 ODNs might selectively target HER -2-overexpressing cells.
Because elevated HER -2 has been identified in only approximately 25 -30% of human breast cancers, is antisense HER -2 therapy useful only for this subpopulation of patients? The studies cited above indicating that this may be the case used only a limited number of breast cancer cell lines. Therefore, we wished to determine if AS HER -2 ODN, alone or in combination with drugs, would also affect breast cancers not expressing elevated levels of HER -2, particularly in light of our recent studies showing that the efficacy of antisense therapy can be significantly improved in combination with conventional radio -and chemotherapy. 18, 19 Thus, we used seven breast adenocarcinoma cell lines, one ductal carcinoma cell line ( ZR -75 -1 ), and, as controls, a breast cell line of a normal karyotype ( MCF -10A ) and a normal human fibroblast cell line ( H500 ). All cells were characterized for their level of HER -2. These relative HER -2 levels (Table 1 ) are mainly consistent with the data of Xie and Hung 21 although here SK -BR -3 cells were found to express less HER -2 than MDA -MB -453, as previously published by Kraus et al. 9 The region spanning the initiation codon of HER -2, 2 nucleotides before it and 10 after, was chosen as a target for a phosphorothioate pentadecamer. This sequence was chosen based on stem and loop structure of the HER -2 mRNA followed by in vitro binding studies with various oligonucleotides designed around the initiation colon region. In addition, a series of AS HER -2 ODNs complementary to the area around and including the initiation codon indicated that this specific oligomer yielded the most efficient inhibition of HER -2 protein synthesis. Uptake of the ODN by adherent cells was facilitated by Lipofectin 1 used at a concentration shown not to produce toxicity. Except for minor variations in the exact targeting of the initiation codon region, these technical details are common for several other studies. 33, 35, 37 In no instance did chemosensitivity correlate with HER -2 overexpression in the cells, i.e., the response to drugs was cell line -specific as previously reported by Pegram et al. 38 Based on the fold of chemosensitization, IC 50 SC /IC 50 AS , and a difference in values of IC 50 AS , determined for breast cancer and control cell lines in the presence of a drug, the combinations of anti -HER -2 ODN and DOX, TAX, or VBL appear to have the most clinical potential.
If taken alone, our data on the antisense response of SK -BR -3 and MCF7 cell lines (Fig 3 ) support the speculation that only HER -2-overexpressing breast cancer cells are affected by AS HER -2 ODN. With 43 copies of the HER -2 gene 39 and a high HER -2 level, SK -BR -3 cells are undoubtedly more responsive to AS ODN than MCF7 cells, where the HER -2 gene is neither amplified nor significantly overexpressed. Although possessing a smaller gene copy number, 9, 39 MDA -MB -453 cells were found to express HER -2 above the protein level found in SK -BR -3 ( Fig 1,  Table 1 ) and were the most responsive to AS HER -2 ODN treatment alone (Figures 2 and 3 ) , thus supporting the significance of overexpression. Furthermore, sequence specificity of AS HER -2 ODN inhibition of HER -2 synthesis was the highest in MDA -MB-453 and SK -BR -3 cells (Fig 2 ) .
However, the inclusion in this study of additional cell lines that do not overexpress HER -2 paints a different picture. In contrast to MCF7, both MDA -MB -435 and MDA -MB -231 cells showed significant response to AS ODN treatment (Figures 2 and 3 ) . Moreover, the degree of AS HER -2 ODN -induced chemosensitization for these two cell lines was consistently among the highest for each of the drugs tested, whereas MCF7 was among the least sensitized ( Tables 2-6 ). These findings indicate that the results of a single cell line cannot be generalized. Doing so may lead to an incorrect assumption. More importantly, these results seem to indicate that it is not necessary for a breast cancer cell to overexpress HER -2 for AS HER -2 ODN to be effective in sensitizing it to conventional chemotherapeutic agents. This is an important finding as it broadens the potential clinical target population for antisense therapy.
The question now becomes why is AS HER -2 so effective in cells that do not overexpress HER -2? One possible answer may lie in the nature of HER -2. The inability to identify a ligand specific for HER -2 has led to the hypothesis that it functions, at least in part, as a coreceptor with the other members of the ErbB family of growth factor receptors. 3 The four ErbB family members, ErbB -1, ErbB -2 /HER -2, ErbB -3, and ErbB -4 form homo -and heterodimer complexes upon ligand binding, thus inducing their kinase activity and producing intracellular signals activating cell growth control pathways such as MAP-kinase. HER -2 has been proposed to be the preferential dimer-mate for each of the other three family members. 2, 4 This results in a signaling network that can respond to a myriad of ligands and interact with a large number of effector proteins, and has been described as a ''neural -like network''. 4 The Ras -Raf -MAP-kinase pathway is the major signaling route for the ErbB family. 40, 41 The intensity and kinetics of MAPK action is apparently determined by the form of the receptor, with heterodimers containing HER -2 being the most active. 4 Thus, Klapper et al 4 have also proposed that the network can be constitutionally active if one of the receptors is mutated or overexpressed. Therefore, this heterodimerization between HER -2 and other family members may explain the results presented here with cell lines that have apparently normal level of HER -2. These and other tumor cell lines may possess abnormalities in other ErbB family members resulting in aberrant cell growth signaling. Because of the preference for HER -2 within the heterodimer complexes, it is conceivable that down -modulation of HER -2 via AS ODN could affect MAPK or other signaling pathways through heterodimers where it is the HER -2 partner, not HER -2 itself, that is abnormal. Support for this hypothesis may be found in the results described above for the low HER -2 expressing MDA -MB -435. This cell line does express HER -3 ( C. Tang and M. Lippman, personnel communication ) and as shown above, treatment with AS HER -2 ODN was clearly able to significantly sensitize this cell line to multiple chemotherapeutic agents with levels of sensitization ranging from almost 8-fold to over 28 -fold. Human breast cancer cell line T47D has been shown to have an elevated level of HER -3 but a very low level of HER -2. 42 We have found that this cell line, as we observed with MDA -MB -231 and MDA -MB -435, could also be sensitized to CDDP (approximately 13-fold ) by AS HER -2 ODN at a concentration as low as 0.3 M (data not shown). Not every breast tumor cell line will necessarily have the same abnormalities. These genetic differences, with respect to this hypothesis, may be one factor influencing the observed differences between the breast cancer cell lines, e.g., MCF7 and MDA -MB -435, used in this study.
Moreover, there is a high level of crosstalk between the innumerable signal transduction pathways that exist within the cell. Down -modulation of HER -2, even if not overexpressed, which is at the head of some of these pathways may, through this crosstalk, also indirectly influence signaling through other pathways in which it is not directly involved.
The apparent broad range of effectiveness of AS HER -2 ODN as shown by the data presented here indicate that this technology could be a viable clinical treatment modality for breast cancer. In particular, the lowering of the effective dose of conventional chemotherapeutic agents, with a concomitant decrease in their toxic side effects, would be of substantial benefit to patients with breast cancer.
